<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43729">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146625</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_HGH_101</org_study_id>
    <nct_id>NCT02146625</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects</brief_title>
  <acronym>hGH</acronym>
  <official_title>A Dose-block Randomized, Single-blind, Placebo-controlled, Single-dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CJ-40002 After Subcutaneous Injection in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  To evaluate the safety and tolerability of CJ-40002 after single SC injection in
           healthy male volunteers.

        -  To evaluate the PK of CJ-40002 after single SC injection in healthy male volunteers.

        -  To evaluate the PD of CJ-40002 after single SC injection in healthy male volunteers.

        -  To evaluate the ADA of CJ-40002 after single SC injection in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC, Cmax</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability (AE's, vital signs, ECG, laboratory tests, local reaction)</measure>
    <time_frame>29 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax, T1/2, CL/F, Vd</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Serum IGF-1, free IGF-1, IGFBP-3, GHBP</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formation of anti-drug antibodies</measure>
    <time_frame>29 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose level 1 of CJ-40002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2 of CJ-40002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3 of CJ-40002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4 of CJ-40002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5 of CJ-40002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-40002</intervention_name>
    <arm_group_label>Dose level 1 of CJ-40002</arm_group_label>
    <arm_group_label>Dose level 2 of CJ-40002</arm_group_label>
    <arm_group_label>Dose level 3 of CJ-40002</arm_group_label>
    <arm_group_label>Dose level 4 of CJ-40002</arm_group_label>
    <arm_group_label>Dose level 5 of CJ-40002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers in the age between 19 and 45 years old (inclusive)

          -  Body mass index (BMI) in the range of 18.5 to 25 kg/m2 and weighing at least 55 kg

          -  Subject who have voluntarily agreed to participate in the trial and signed the
             written informed consent form, after having listened to the purpose, method, and
             effect of the clinical trial

        Exclusion Criteria:

          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric,
             musculoskeletal or cardiovascular disease or any other condition

          -  History of allergy or sensitivity to any drug

          -  Subject with the following clinically significant laboratory abnormalities:

               -  AST or ALT &gt; 1.25 x Upper Limit Normal (ULN)

               -  Total bilirubin &gt; 1.5 x Upper Limit Normal (ULN)

               -  CPK &gt; 1.5 x Upper Limit Normal (ULN)

               -  eGFR &lt; 60 mL/min/1.73 m2

          -  Systolic blood pressure outside the range of 90 to 150 mmHg or diastolic blood
             pressure outside the range of 50 to 100 mmHg

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

          -  Participation in any clinical investigation within 60days prior to study medication
             dosing

          -  Subjects with whole blood donation within 60days, component blood donation within
             30days prior to study medication dosing

          -  Positive test results for HBs Ab, HCV Ab, HIV test

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geun Seog Song, PhD</last_name>
    <phone>82-2-6740-2440</phone>
    <email>kssong1212@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun Ji Kim</last_name>
    <phone>82-2-6740-2443</phone>
    <email>keunji@cj.net</email>
  </overall_contact_backup>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
